Celcuity (CELC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
2 Apr, 2026Voting matters and shareholder proposals
Election of eight directors is proposed, with all nominees recommended for approval by the board.
Ratification of Boulay PLLP as the independent registered public accounting firm for the year ending December 31, 2026 is up for vote.
Advisory approval of named executive officer compensation is included as a voting item.
Approval of the 2026 Stock Incentive Plan and the Amended and Restated Employee Stock Purchase Plan are proposed.
Proxies may vote on other business that may properly come before the meeting.
Board of directors and corporate governance
Eight director nominees are listed for election at the annual meeting.
Executive compensation and say-on-pay
Advisory vote on executive compensation is scheduled, allowing shareholders to express approval or disapproval.
A new 2026 Stock Incentive Plan and an amended Employee Stock Purchase Plan are proposed for approval.
Latest events from Celcuity
- FDA approval, strong trial data, and robust cash position support late Q3 launch and growth.CELC
Q2 2026 - REVTORPYK delivers best-in-class efficacy for HR+/HER2- breast cancer with strong market potential.CELC
Corporate presentation - FDA approved REVTORPYK for HR+/HER2-, PIK3CA wild-type advanced breast cancer; launch late Q3 2026.CELC
FDA announcement - Gedatolisib doubled PFS and set new efficacy benchmarks, with major regulatory milestones ahead.CELC
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Gedatolisib's phase III data show doubled PFS, supporting its potential as a new breast cancer standard.CELC
Jefferies Global Healthcare Conference 2026 - Gedatolisib regimens doubled PFS and set new efficacy benchmarks in advanced breast cancer.CELC
Study result - Positive Phase 3 data and FDA Priority Review set stage for 2026 launch; net loss at $52.8M.CELC
Q1 2026 - Shareholders will vote on directors, auditor, executive pay, and new equity plans at the 2026 meeting.CELC
Proxy filing - Strong Phase 3 data and $455M cash position support NDA submission and future commercialization.CELC
Q3 2025